MIRM

AI MemoPost-earnings T+3

Mirum

As of 2026-05-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Zilurgisertib Priority Review adds a new rare-disease launch option in 2026 • 2026-09-26

Expected move: +28%

Biggest risk

Forward value still depends on several binary development and regulatory milestones, while Q1 GAAP results were heavily distorted by the Bluejay acquisition, including a $726.3 million acquired IPR&D charge and accelerated Bluejay stock compensation; the 10-Q also shows the 2029 converts are currently holder-convertible during Q2 2026, adding balance-sheet and dilution overhang [#10-Q-2026-05-06].

Invalidation

Break below $82 or thesis failure.

What would change my mind?

The checked evidence supports a constructive post-print read: strong Q1 product sales, a 2026 guide raise, positive recent VISTAS and AZURE-1 milestone language in the earnings update, and a cash position that management says supports operations for at least 12 months [#8-K-2026-05-06] [#10-Q-2026-05-06].

Research note

Recommendation

—

Confidence

medium

As of

2026-05-08

Base target

$118

p=45%

Bull target

$135

p=30%

Bear target

$82

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 2026 update raised revenue guidance and reinforced commercial execution
Brelovitug AZURE topline data can open a 2027 BLA path
EXPAND topline data could broaden LIVMARLI’s label beyond current settings

BearKey bullets

Late-2026 pipeline value remains highly dependent on successful AZURE and EXPAND readouts, with normal biotech binary-risk around efficacy, safety, and regulatory interpretation.
Mirum’s March 31, 2026 10-Q states its 4.00% convertible senior notes due 2029 are convertible at holders’ option during the second quarter of 2026, creating potential cash-use or dilution sensitivity depending on settlement choices.
The 10-Q still describes Mirum as having a limited operating history and an accumulated deficit of about $1.5 billion as of March 31, 2026, so sustained valuation support still requires continued commercial growth and successful development execution.

WatchKey bullets

Zilurgisertib Priority Review adds a new rare-disease launch option in 2026

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $118 (p=45%)

Bull/Bear spread: +46% / -11%

Vs latest close: Bull +46% · Base +28% · Bear -11%

Scenario probabilities

Bull Target: $135 (p=30%)Base Target: $118 (p=45%)Bear Target: $82 (p=25%)

Commentary

News flow is clearly constructive into May 2026: positive VISTAS headlines on May 4 and a beat-and-raise style earnings update on May 6. Immediate reaction evidence is mixed in low-trust market summaries, but the verified tape shows MIRM closed at $102.93 on May 7, 2026 and traded at $107.16 on May 8, 2026, indicating the post-release setup remained positive. Analyst revision visibility was still limited in the checked sources, so this remains a cautious positive-monitoring view rather than a high-conviction post-earnings upgrade.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 2026 update raised revenue guidance and reinforced commercial execution
Brelovitug AZURE topline data can open a 2027 BLA path
EXPAND topline data could broaden LIVMARLI’s label beyond current settings

Scenarios

Bull Target (Scenario probability)

$135 / p=30% prob

Base Target (Scenario probability)

$118 / p=45% prob

Bear Target (Scenario probability)

$82 / p=25% prob

Price $92 as of 2026-06-02

Nearest Scenario: Bear (∆ 11%)

Targets vs latest close: Bull +46% · Base +28% · Bear -11%

Sentiment & Exposure

News Sentiment (30d)

0.66

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-26
Zilurgisertib Priority Review adds a new rare-disease launch option in 2026
Mirum disclosed in its March 31, 2026 10-Q that it entered an April 2026 agreement with Incyte to obtain commercialization rights to zilurgisertib upon FDA approval, and that the NDA has been accepted with a September 26, 2026 PDUFA date, creating a discrete regulatory catalyst outside the existing cholestatic liver and HDV programs [#10-Q-2026-05-06].
Prob 65.00% • Move 11.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Q1 2026 update raised revenue guidance and reinforced commercial execution
2026-05-06
Mirum’s May 6, 2026 earnings update highlighted Q1 2026 net product sales of $159.9 million, a raise in 2026 net product sales guidance to $660 million-$680 million from the prior $630 million-$650 million range, and unrestricted cash, cash equivalents and investments of $420.6 million as of March 31, 2026; the same filing also notes the update was furnished on Form 8-K and provides at least 12 months of operating runway [#8-K-2026-05-06] [#10-Q-2026-05-06].
Prob 80% • Move 9% • Priced-in 60%

Long-term Catalysts

Months to a year

Brelovitug AZURE topline data can open a 2027 BLA path
2026-10-31
Mirum said on March 5, 2026 that AZURE-1 enrollment and AZURE-4 screening were complete, with topline 24-week data expected in the second half of 2026 and the two studies intended to support a U.S. BLA submission; this is one of the company’s largest pipeline value drivers but remains binary and integration-sensitive.
Prob 60% • Move 18% • Priced-in 40%
EXPAND topline data could broaden LIVMARLI’s label beyond current settings
2026-11-15
Mirum announced on March 16, 2026 that enrollment was complete in the Phase 3 EXPAND study of LIVMARLI in additional rare cholestatic liver diseases, with topline data expected in Q4 2026, offering a lower-risk label-expansion path tied to an already commercialized platform.
Prob 62% • Move 12% • Priced-in 42%

Risks

Late-2026 pipeline value remains highly dependent on successful AZURE and EXPAND readouts, with normal biotech binary-risk around efficacy, safety, and regulatory interpretation.
Mirum’s March 31, 2026 10-Q states its 4.00% convertible senior notes due 2029 are convertible at holders’ option during the second quarter of 2026, creating potential cash-use or dilution sensitivity depending on settlement choices.
The 10-Q still describes Mirum as having a limited operating history and an accumulated deficit of about $1.5 billion as of March 31, 2026, so sustained valuation support still requires continued commercial growth and successful development execution.
The Bluejay acquisition meaningfully increased reported expense and complexity; the 10-Q shows a $726.3 million acquired IPR&D charge plus accelerated Bluejay stock compensation, which can obscure underlying earnings quality and raise execution risk.

Peers

Symbol	Summary
PTGX	Protagonist is the closest-sized packet peer for event-driven biotech valuation, though its GI/immunology focus makes it only a loose operating comp; it is useful mainly for comparing pipeline-premium sensitivity and binary-readout trading.
GILD	Gilead is not a size match, but it is relevant as a liver-disease and antiviral benchmark; Mirum’s HDV and cholestatic-liver assets can be framed against a far larger commercial and regulatory execution platform.
REGN	Regeneron is a loose large-cap biotech comp for how investors value funded pipelines plus commercial durability; the comparison mainly highlights that Mirum still trades on a much narrower set of catalysts and less diversification.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-08

AI Stock Memo: MIRM - Mirum - RankAlpha